Emergent BioSolutions (NYSE:EBS) Raised to Buy at StockNews.com

Emergent BioSolutions (NYSE:EBS) was upgraded by research analysts at StockNews.com from a “hold” rating to a “buy” rating in a research report issued on Monday.

Other analysts have also recently issued reports about the stock. HC Wainwright restated a “buy” rating and set a $15.00 price objective on shares of Emergent BioSolutions in a research note on Tuesday, January 21st. Benchmark lifted their price objective on shares of Emergent BioSolutions from $8.00 to $12.00 and gave the company a “buy” rating in a research note on Thursday, November 7th.

Emergent BioSolutions Stock Down 13.9 %

NYSE:EBS opened at $8.37 on Monday. The company has a market cap of $453.25 million, a PE ratio of -2.04 and a beta of 1.62. Emergent BioSolutions has a twelve month low of $1.48 and a twelve month high of $15.10. The company has a current ratio of 2.88, a quick ratio of 1.47 and a debt-to-equity ratio of 1.30. The company’s 50 day moving average is $9.71 and its two-hundred day moving average is $9.12.

Hedge Funds Weigh In On Emergent BioSolutions

Several large investors have recently made changes to their positions in the company. Alpine Global Management LLC acquired a new position in shares of Emergent BioSolutions in the 4th quarter valued at $112,000. Two Sigma Advisers LP lifted its stake in shares of Emergent BioSolutions by 14.1% in the 4th quarter. Two Sigma Advisers LP now owns 656,500 shares of the biopharmaceutical company’s stock valued at $6,276,000 after purchasing an additional 81,000 shares during the period. Two Sigma Investments LP lifted its stake in shares of Emergent BioSolutions by 13.9% in the 4th quarter. Two Sigma Investments LP now owns 846,766 shares of the biopharmaceutical company’s stock valued at $8,095,000 after purchasing an additional 103,574 shares during the period. State of Wyoming lifted its stake in shares of Emergent BioSolutions by 118.2% in the 4th quarter. State of Wyoming now owns 39,076 shares of the biopharmaceutical company’s stock valued at $374,000 after purchasing an additional 21,165 shares during the period. Finally, Point72 Asia Singapore Pte. Ltd. lifted its stake in shares of Emergent BioSolutions by 408.4% in the 4th quarter. Point72 Asia Singapore Pte. Ltd. now owns 42,712 shares of the biopharmaceutical company’s stock valued at $408,000 after purchasing an additional 34,311 shares during the period. 78.40% of the stock is currently owned by institutional investors and hedge funds.

Emergent BioSolutions Company Profile

Emergent BioSolutions Inc, a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States. The company offers NARCAN Nasal Spray for the emergency treatment of known or suspected opioid overdose; Vaxchora vaccine for the prevention of cholera; Vivotif vaccine for oral administration for the prevention of typhoid fever; Anthrasil for the treatment of inhalational anthrax; BioThrax, an anthrax vaccine; CYFENDUS for post-exposure prophylaxis of disease following suspected or confirmed exposure to Bacillus anthracis; and Raxibacumab injection for the treatment and prophylaxis of inhalational anthrax.